Mitochondrial Dynamics of Ovarian Cells and Polycystic Ovary Syndrome

doi:10.12280/gjfckx.20200838

Abstract

Abstract:

Polycystic ovary syndrome (PCOS) is one of the endocrine diseases in women. The aberrant expression of key factors regulating mitochondrial dynamic balance found in granulosa cells of PCOS patients suggested reduced ability of ovarian cells to clear mitochondria with abnormal function. The accumulation of abnormal mitochondria in ovarian cells not only affect the insulin sensitivity and steroid hormone synthesis ability of cells, but also directly reduce the ability of follicle cells to support oocyte development. The abnormal insulin signaling pathway within ovarian cells of PCOS patients may cause abnormal mitochondrial accumulation in cells by interfering the mitochondrial dynamic of ovarian cells and oocytes. We speculated the abnormal mitochondrial dynamic of ovarian cells might relate to the abnormal reproductive function in PCOS patients and that may be the key node between insulin resistance and the abnormal ovarian function in PCOS patients, however, the development of clinical treatment based on this mechanism still need further research.

Key words: Polycystic ovary syndrome, Mitochondrial dynamics, Phosphatidylinositol 3-kinases, Metabolic syndrome, Mammalian target of rapamyoin

LI Wei, FAN Rui-feng, XU Qiu-hong, CHEN Jing, WU Xiao-ke, KUANG Hong-ying, WANG Ying-ji, LI Yan. Mitochondrial Dynamics of Ovarian Cells and Polycystic Ovary Syndrome[J]. Journal of International Obstetrics and Gynecology, 2021, 48(4): 403-408.

References 35

[1]	Banaszewska B, Pawelczyk L, Spaczynski R. Current and future aspects of several adjunctive treatment strategies in polycystic ovary syndrome[J]. Reprod Biol, 2019, 19(4):309-315. doi: 10.1016/j.repbio.2019.09.006. doi: S1642-431X(19)30206-2 pmid: 31606349
[2]	Ilie IR. Advances in PCOS Pathogenesis and Progression-Mitochondrial Mutations and Dysfunction[J]. Adv Clin Chem, 2018, 86(3):127-155. doi: 10.1016/bs.acc.2018.05.003. doi: 10.1016/bs.acc.2018.05.003
[3]	Salehi R, Mazier HL, Nivet AL, et al. Ovarian mitochondrial dynamics and cell fate regulation in an androgen-induced rat model of polycystic ovarian syndrome[J]. Sci Rep, 2020, 10(1):1021. doi: 10.1038/s41598-020-57672-w. doi: 10.1038/s41598-020-57672-w pmid: 31974436
[4]	Mitra K, Rikhy R, Lilly M, et al. DRP1-dependent mitochondrial fission initiates follicle cell differentiation during Drosophila oogenesis[J]. J Cell Biol, 2012, 197(4):487-497. doi: 10.1083/jcb.201110058. doi: 10.1083/jcb.201110058
[5]	Zhang M, Bener MB, Jiang Z, et al. Mitofusin 1 is required for female fertility and to maintain ovarian follicular reserve[J]. Cell Death Dis, 2019, 10(8):560. doi: 10.1038/s41419-019-1799-3. doi: 10.1038/s41419-019-1799-3 pmid: 31332167
[6]	张敏, 杜馨, 李贝贝, 等. 卵母细胞线粒体DNA与胚胎质量的相关性研究进展[J]. 国际生殖健康/计划生育杂志, 2020, 39(6):486-489.
[7]	López-Lluch G. Mitochondrial activity and dynamics changes regarding metabolism in ageing and obesity[J]. Mech Ageing Dev, 2017, 162:108-121. doi: 10.1016/j.mad.2016.12.005. doi: S0047-6374(16)30104-X pmid: 27993601
[8]	Udagawa O, Ishihara T, Maeda M, et al. Mitochondrial fission factor Drp1 maintains oocyte quality via dynamic rearrangement of multiple organelles[J]. Curr Biol, 2014, 24(20):2451-2458. doi: 10.1016/j.cub.2014.08.060. doi: 10.1016/j.cub.2014.08.060 pmid: 25264261
[9]	Luan G, Li G, Ma X, et al. Dexamethasone-Induced Mitochondrial Dysfunction and Insulin Resistance-Study in 3T3-L1 Adipocytes and Mitochondria Isolated from Mouse Liver[J]. Molecules, 2019, 24(10):1982. doi: 10.3390/molecules24101982. doi: 10.3390/molecules24101982
[10]	Fazakerley DJ, Chaudhuri R, Yang P, et al. Mitochondrial CoQ deficiency is a common driver of mitochondrial oxidants and insulin resistance[J]. Elife, 2018, 7:e32111. doi: 10.7554/eLife.32111. doi: 10.7554/eLife.32111
[11]	Bañuls C, Rovira-Llopis S, Martinez de Marañon A, et al. Metabolic syndrome enhances endoplasmic reticulum, oxidative stress and leukocyte-endothelium interactions in PCOS[J]. Metabolism, 2017, 71:153-162. doi: 10.1016/j.metabol.2017.02.012. doi: 10.1016/j.metabol.2017.02.012
[12]	Ding Y, Xia BH, Zhang CJ, et al. Mitochondrial tRNA(Leu(UUR)) C3275T, tRNA(Gln) T4363C and tRNA(Lys) A8343G mutations may be associated with PCOS and metabolic syndrome[J]. Gene, 2018, 642:299-306. doi: 10.1016/j.gene.2017.11.049. doi: S0378-1119(17)31013-2 pmid: 29155328
[13]	Rogowicz-Frontczak A, Majchrzak A, Zozulińska-Ziółkiewicz D. Insulin resistance in endocrine disorders-treatment options[J]. Endokrynol Pol, 2017, 68(3):334-351. doi: 10.5603/EP.2017.0026. doi: 10.5603/EP.2017.0026 pmid: 28660991
[14]	Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypojournal of PCOS as Functional Ovarian Hyperandrogenism Revisited[J]. Endocr Rev, 2016, 37(5):467-520. doi: 10.1210/er.2015-1104. doi: 10.1210/er.2015-1104 pmid: 27459230
[15]	Karuputhula NB, Chattopadhyay R, Chakravarty B, et al. Oxidative status in granulosa cells of infertile women undergoing IVF[J]. Syst Biol Reprod Med, 2013, 59(2):91-98. doi: 10.3109/19396368.2012.743197. doi: 10.3109/19396368.2012.743197 pmid: 23278116
[16]	Jia L, Zeng Y, Hu Y, et al. Homocysteine impairs porcine oocyte quality via deregulation of one-carbon metabolism and hypermethylation of mitochondrial DNA?[J]. Biol Reprod, 2019, 100(4):907-916. doi: 10.1093/biolre/ioy238. doi: 10.1093/biolre/ioy238
[17]	Randriamboavonjy V, Mann WA, Elgheznawy A, et al. Metformin reduces hyper-reactivity of platelets from patients with polycystic ovary syndrome by improving mitochondrial integrity[J]. Thromb Haemost, 2015, 114(3):569-578. doi: 10.1160/TH14-09-0797. doi: 10.1160/TH14-09-0797
[18]	Abbade J, Klemetti MM, Farrell A, et al. Increased placental mitochondrial fusion in gestational diabetes mellitus: an adaptive mechanism to optimize feto-placental metabolic homeostasis?[J]. BMJ Open Diabetes Res Care, 2020, 8(1):e000923. doi: 10.1136/bmjdrc-2019-000923. doi: 10.1136/bmjdrc-2019-000923
[19]	Zimmermann M, Reichert AS. How to get rid of mitochondria: crosstalk and regulation of multiple mitophagy pathways[J]. Biol Chem, 2017, 399(1):29-45. doi: 10.1515/hsz-2017-0206. doi: 10.1515/hsz-2017-0206 pmid: 28976890
[20]	Atef MM, Abd-Ellatif RN, Emam MN, et al. Therapeutic potential of sodium selenite in letrozole induced polycystic ovary syndrome rat model: Targeting mitochondrial approach (selenium in PCOS)[J]. Arch Biochem Biophys, 2019, 671:245-254. doi: 10.1016/j.abb.2019.06.009. doi: 10.1016/j.abb.2019.06.009
[21]	Qi L, Liu B, Chen X, et al. Single-Cell Transcriptomic Analysis Reveals Mitochondrial Dynamics in Oocytes of Patients With Polycystic Ovary Syndrome[J]. Front Genet, 2020, 11:396. doi: 10.3389/fgene.2020.00396. doi: 10.3389/fgene.2020.00396
[22]	Gao T, Zhang X, Zhao J, et al. SIK2 promotes reprogramming of glucose metabolism through PI3K/AKT/HIF-1α pathway and Drp1-mediated mitochondrial fission in ovarian cancer[J]. Cancer Lett, 2020, 469:89-101. doi: 10.1016/j.canlet.2019.10.029. doi: 10.1016/j.canlet.2019.10.029
[23]	Yao X, Zhang J, Jing X, et al. Fibroblast growth factor 18 exerts anti-osteoarthritic effects through PI3K-AKT signaling and mitochondrial fusion and fission[J]. Pharmacol Res, 2019, 139:314-324. doi: 10.1016/j.phrs.2018.09.026. doi: 10.1016/j.phrs.2018.09.026
[24]	He T, Liu Y, Zhao S, et al. Comprehensive assessment the expression of core elements related to IGFIR/PI3K pathway in granulosa cells of women with polycystic ovary syndrome[J]. Eur J Obstet Gynecol Reprod Biol, 2019, 233:134-140. doi: 10.1016/j.ejogrb.2018.12.010. doi: 10.1016/j.ejogrb.2018.12.010
[25]	Morita M, Prudent J, Basu K, et al. mTOR Controls Mitochondrial Dynamics and Cell Survival via MTFP1[J]. Mol Cell, 2017, 67（6）:922-935.e5. doi: 10.1016/j.molcel.2017.08.013. doi: 10.1016/j.molcel.2017.08.013
[26]	Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR Signaling in Cancer[J]. Front Oncol, 2014, 4:64. doi: 10.3389/fonc.2014.00064. doi: 10.3389/fonc.2014.00064
[27]	Song WJ, Shi X, Zhang J, et al. Akt-mTOR Signaling Mediates Abnormalities in the Proliferation and Apoptosis of Ovarian Granulosa Cells in Patients with Polycystic Ovary Syndrome[J]. Gynecol Obstet Invest, 2018, 83(2):124-132. doi: 10.1159/000464351. doi: 10.1159/000464351
[28]	Yaba A, Demir N. The mechanism of mTOR (mammalian target of rapamycin) in a mouse model of polycystic ovary syndrome (PCOS)[J]. J Ovarian Res, 2012, 5(1):38. doi: 10.1186/1757-2215-5-38. doi: 10.1186/1757-2215-5-38
[29]	Luo QY, Huo P, Wang LL, et al. The influencing mechanism of mTOR signal pathway mediated by mitofusin-2 in development of follicle[J]. Eur Rev Med Pharmacol Sci, 2018, 22(8):2212-2217. doi: 10.26355/eurrev_201804_14806. doi: 10.26355/eurrev_201804_14806
[30]	Zhang J, Liu W, Sun X, et al. Inhibition of mTOR Signaling Pathway Delays Follicle Formation in Mice[J]. J Cell Physiol, 2017, 232(3):585-595. doi: 10.1002/jcp.25456. doi: 10.1002/jcp.25456 pmid: 27301841
[31]	Jamilian M, Samimi M, Mirhosseini N, et al. The influences of vitamin D and omega-3 co-supplementation on clinical, metabolic and genetic parameters in women with polycystic ovary syndrome[J]. J Affect Disord, 2018, 238:32-38. doi: 10.1016/j.jad.2018.05.027. doi: 10.1016/j.jad.2018.05.027
[32]	Safaei Z, Bakhshalizadeh SH, Nasr Esfahani MH, et al. Effect of Vitamin D3 on Mitochondrial Biogenesis in Granulosa Cells Derived from Polycystic Ovary Syndrome[J]. Int J Fertil Steril, 2020, 14(2):143-149. doi: 10.22074/ijfs.2020.6077. doi: 10.22074/ijfs.2020.6077 pmid: 32681627
[33]	Kyei G, Sobhani A, Nekonam S, et al. Assessing the effect of MitoQ(10) and Vitamin D3 on ovarian oxidative stress, steroidogenesis and histomorphology in DHEA induced PCOS mouse model[J]. Heliyon, 2020, 6(7):e04279. doi: 10.1016/j.heliyon.2020.e04279. doi: 10.1016/j.heliyon.2020.e04279
[34]	Cheng H, Gang X, Liu Y, et al. Mitochondrial dysfunction plays a key role in the development of neurodegenerative diseases in diabetes[J]. Am J Physiol Endocrinol Metab, 2020, 318(5):E750-E764. doi: 10.1152/ajpendo.00179.2019. doi: 10.1152/ajpendo.00179.2019
[35]	Skov V, Glintborg D, Knudsen S, et al. Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynjournal in skeletal muscle in polycystic ovary syndrome[J]. PLoS One, 2008, 3(6):e2466. doi: 10.1371/journal.pone.0002466. doi: 10.1371/journal.pone.0002466